Humulina Nph

Humulina Nph is a prescription injectable suspension containing insulin human. It is formulated as a neutral protamine Hagedorn (NPH) intermediate‑acting insulin for subcutaneous or intramuscular use. Marketed in the European Union, this antidiabetic drug is used to help regulate blood glucose in patients with type 1 or type 2 diabetes and is typically prescribed as part of a broader diabetes management plan under medical supervision and regular follow‑up.

Humulina Nph is prescribed for patients who need basal insulin coverage to maintain stable blood glucose levels.

- Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen. - Type 2 diabetes mellitus when oral agents are insufficient or as initial therapy in insulin‑requiring patients. - Combination with rapid‑acting insulin analogues for intensified insulin therapy. - Use as adjunct therapy with oral antidiabetic drugs such as metformin or sulfonylureas. - Basal insulin support during periods of increased insulin resistance, such as illness or steroid therapy.

Adverse reactions to Humulina Nph may occur, ranging from mild injection‑site symptoms to rare but serious systemic events.

Common: - Localized redness, swelling, or itching at the injection site. - Mild hypoglycemia, especially if meals are missed or delayed. - Weight gain associated with improved glycemic control. - Lipodystrophy (fat tissue changes) at repeated injection sites. - Transient headache or dizziness. - Injection site bruising or hematoma.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Edema or fluid retention causing peripheral swelling. - Hypersensitivity with fever, chills, or malaise. - Unexplained weight loss or catabolism. - Persistent hyperglycemia despite dose adjustments, indicating possible insulin resistance.

When prescribing Humulina Nph, clinicians should consider several precautionary measures to ensure safe and effective use.

- Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance. - Educate patients on recognizing and treating hypoglycemia, including the 15‑15 rule. - Adjust doses during periods of illness, surgery, or when using corticosteroids. - Monitor weight and signs of fluid retention, especially in patients with cardiac disease. - Avoid use in patients with known hypersensitivity to protamine or insulin preparations. - Consider pregnancy status; the safety profile in pregnancy is not well established. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulina Nph can interact with other agents that affect glucose metabolism or insulin action; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low blood sugar. - High‑dose corticosteroids that markedly increase insulin resistance.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, which can potentiate hypoglycemia; dose titration is required. - Diuretics, especially thiazides, that may raise blood glucose levels. - Alcohol consumption, which can cause unpredictable glucose fluctuations. - MAO‑inhibitors or other drugs that interfere with carbohydrate metabolism.